Your browser doesn't support javascript.
loading
Programmed death-ligand 1 expression in the immune compartment of colon carcinoma.
Yilmaz, Osman; Pankaj, Amaya; Neyez, Azfar; Rickelt, Steffen; Taylor, Martin; Lang, Evan R; Leijsen, Lieve; Dinaux, Anne; Shroff, Stuti G; Crotty, Rory; Zhang, M Lisa; Cerda, Sandra; Zhao, Qing; Ferrone, Cristina; Ting, David T; Patil, Deepa T; Yilmaz, Omer; Berger, David; Deshpande, Vikram.
Afiliação
  • Yilmaz O; Department of Pathology, Boston Medical Center, Boston, MA, 02114, USA.
  • Pankaj A; Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, 02114, USA.
  • Neyez A; Department of Pathology, Massachusetts General Hospital, Boston, MA, 02114, USA.
  • Rickelt S; Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, 15213, USA.
  • Taylor M; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
  • Lang ER; Department of Pathology, Massachusetts General Hospital, Boston, MA, 02114, USA.
  • Leijsen L; Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, 02114, USA.
  • Dinaux A; Department of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA.
  • Shroff SG; Department of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA.
  • Crotty R; Department of Pathology, Massachusetts General Hospital, Boston, MA, 02114, USA.
  • Zhang ML; Department of Pathology, Massachusetts General Hospital, Boston, MA, 02114, USA.
  • Cerda S; Department of Pathology, Massachusetts General Hospital, Boston, MA, 02114, USA.
  • Zhao Q; Department of Pathology, Boston Medical Center, Boston, MA, 02114, USA.
  • Ferrone C; Department of Pathology, Boston Medical Center, Boston, MA, 02114, USA.
  • Ting DT; Department of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA.
  • Patil DT; Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, 02114, USA.
  • Yilmaz O; Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
  • Berger D; Department of Pathology, Massachusetts General Hospital, Boston, MA, 02114, USA.
  • Deshpande V; Department of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA.
Mod Pathol ; 35(11): 1740-1748, 2022 11.
Article em En | MEDLINE | ID: mdl-35773332
ABSTRACT
Programmed cell death ligand 1 (PD-L1) on tumor cells is a significant prognostic biomarker for a number of malignancies, although less is known about the significance of PD-L1 positive immune cells in colon carcinoma. The purpose of this study is to evaluate the role of PD-L1 in a large cohort of colon carcinomas to identify patterns of PD-L1 expression in the tumor microenvironment and its correlation with other key immune subsets to better understand the impact of these immune cells. We assessed 1218 colon carcinomas on representative tissue microarray sections, gathered relevant clinicopathologic information, and performed immunohistochemical staining for mismatch repair proteins, CD8, CD163, LAG3, PD-L1, FoxP3, and BRAF V600E. We then performed automated quantification; manual quantification was used for PD-L1 tumor cells and immune cells. Dual PD-L1/PU.1 immunostain was also performed. The majority of PD-L1 positive cells expressed PU.1 thus representing tumor-associated macrophages. Based on the median number of PD-L1 positive immune cells (7.6/mm2), we classified tumors into two classes (1) PD-L1 immune cell low and (2) PD-L1 immune cell high. PD-L1 immune cell high colon carcinomas showed favorable prognostic pathologic features including less frequent extramural venous invasion (p = 0.0001) and lower AJCC stage (p = 0.0001); they were also more commonly associated with deficient mismatch repair (dMMR) (p = 0.0001) and BRAF V600E reactivity. PD-LI immune cell high tumors were associated with high CD8, CD163, and FoxP3 positive cells (p = 0.0001, respectively). PD-L1 immune cell high and LAG3 high colon carcinomas were associated with improved disease-specific survival (p = 0.0001 and 0.001, respectively). PD-L1 expression on tumor cells was not associated with disease-specific survival. On multivariate analysis of chemotherapy naïve stage 2 colon carcinomas, only extramural venous invasion (p = 0.002), perineural invasion (p = 0.001) and PD-L1 immune cell expression (p = 0.032) correlated with disease-specific survival. Resected colonic carcinomas with high expression of PD-L1 and LAG3 proteins on immune cells were associated with improved prognosis in colon carcinoma. The mechanism underlying the improved prognosis of colon carcinomas bearing high numbers of immunoregulatory cells needs further investigation.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma / Neoplasias do Colo Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Mod Pathol Assunto da revista: PATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma / Neoplasias do Colo Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Mod Pathol Assunto da revista: PATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos